| Título: | Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis |
| Autores: |
Qin, T.; Sun Yat-sen University Cancer Center Yuan, Z.Y.; Sun Yat-sen University Cancer Center Peng, R.J.; Sun Yat-sen University Cancer Center Zeng, Y.D.; Sun Yat-sen University Shi, Y.X.; Sun Yat-sen University Cancer Center Teng, X.Y.; Sun Yat-sen University Cancer Center Liu, D.G.; Sun Yat-sen University Cancer Center Bai, B.; Sun Yat-sen University Cancer Center Wang, S.S.; Sun Yat-sen University Cancer Center |
| Fecha: | 2013-08-06 |
| Publicador: | Multimed Inc. |
| Fuente: |
Ver documento |
| Tipo: |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| Tema: | Tamoxifen; toremifene; breast cancer; adjuvant endocrine therapy; premenopausal |
| Descripción: | BackgroundGiven the use of tamoxifen as standard treatment for hormone receptor–positive breast cancer, the use of toremifene as an adjuvant endocrine therapy has not been widely examined. The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor–positive breast cancer in premenopausal women.MethodsPremenopausal patients with hormone receptor– positive operable breast cancer were eligible. Enrolled patients (n = 1847) received either 60 mg toremifene (n = 396) or 20 mg tamoxifen (n = 1451) daily for a minimum of 5 years after surgery. Disease-free survival (dfs) was the primary endpoint. Overall survival (os) and time to distant recurrence were secondary endpoints.ResultsTreatment with toremifene and tamoxifen resulted in no between-group differences in dfs (p = 0.659) or os (p = 0.364). Mean dfs was 10.3 years for both groups. Mean os was 11.2 years for the toremifene group and 11.1 years for tamoxifen group. The 5-year dfs rate was 87.0% in the toremifene group and 85.0% in the tamoxifen group. The 5-year survival rate was 94.3% in the toremifene group and 93.5% in the tamoxifen group. Adverse events rates were similar in the two groups, with the exception of irregular menses, which occurred at a higher rate in the tamoxifen group than in the toremifene group (10.0% vs. 6.3%, p = 0.025).ConclusionsIn this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor–positive breast cancer in premenopausal women were similar. |
| Idioma: | Inglés |
1 Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind por Sagar, Stephen,Dryden, Trish; Centre for Applied Research, Centennial College,Wong, Raimond K; McMaster University, Departments of Medicine and Oncology | 6 |
2 Chinese Medicine and Biomodulation in Cancer Patients (Part Two) por Sagar, Stephen M,Wong, Raimond K | 7 Cord stem-cell transplantation in Ontario: do we need a public bank? por Gassas, A.; the Hospital for Sick Children, Toronto |
3 Integrating Science and Human Values for Cancer Patient Care por Sutcliffe, Simon B.; BC Cancer Agency | 8 Assessment and management of febrile neutropenia in emergency departments within a regional health authority—a benchmark analysis por Szwajcer, D.; University of Manitoba,Czaykowski, P.; University of Manitoba,Turner, D.; CancerCare Manitoba |
4 Conservative Treatment of Invasive Bladder Cancer por Souhami, Luis; McGill University,Rene, Nicholas,Cury, Fabio Biagini | 9 Liver transplantation for symptomatic liver metastases of neuroendocrine tumours por Chan, G.; Hôpital Maisonneuve-Rosemont
Université de Montréal,Kocha, W.,Reid, R.,Taqi, A.,Wall, W.,Quan, D. |
5 A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital por Chin, S. N.,Wang, L.,Moore, M.,Sridhar, S. S.; University of Toronto | 10 What is the optimal management of dysphagia in metastatic esophageal cancer? por Cavallin, F.; Veneto Institute of Oncology,Scarpa, M.; Veneto Institute of Oncology,Cagol, M.; Veneto Institute of Oncology,Alfieri, R.; Veneto Institute of Oncology,Castoro, C.; Veneto Institute of Oncology |